Key Highlights

Risk & Performance

Pipeline Risk Assessment

Based on historical performance

Moderate Risk

Score: 45/100

Failure Rate

0.0%

0 terminated/withdrawn out of 7 trials

Success Rate

100.0%

+13.5% vs industry average

Late-Stage Pipeline

14%

1 trials in Phase 3/4

Results Transparency

0 of 1 completed trials have results

Key Signals

Enrollment Performance

Analytics

N/A

4(80.0%)

Phase 3

1(20.0%)

5Total

N/A(4)

Phase 3(1)

Activity Timeline

Global Presence

Loading network data...

Clinical Trials (7)

Showing 7 of 7 trials

NCT03500809Not ApplicableUnknown

Aqueous Release to Treat IOP Spikes Post-cataract Surgery

Role: lead

NCT03530735Not ApplicableUnknown

Finger-prick Autologous Blood (FAB) for Use in Dry Mouth

Role: lead

NCT03395431Not ApplicableUnknown

Fingerprick Autologous Blood (FAB) in Severe Dry Eye Disease (DED)

Role: lead

NCT02943382Not ApplicableUnknown

Fingerprick Autologous Blood (FAB) in Mebomian Gland Dysfunction (MGD)

Role: lead

NCT02153515Phase 3Unknown

Treating Dry Eyes and Corneal Ulcers With Fingerprick Autologous Blood

Role: lead

NCT02849093Unknown

Optical Coherence Tomography of Ocular Structures in Epiphora and Dry Eye Syndrome.

Role: lead

NCT00357812Completed

The Efficacy of Two Potential Diagnostic Assays for Herpes Simplex Keratitis (HSK)

Role: collaborator

All 7 trials loaded